Cem Mirili1, Ali Yılmaz2, Serkan Demirkan3, Mehmet Bilici2, Salim Basol Tekin2. 1. Department of Medical Oncology, Ataturk University Faculty of Medicine, 25050, Yakutiye, Erzurum, Turkey. cemirili@gmail.com. 2. Department of Medical Oncology, Ataturk University Faculty of Medicine, 25050, Yakutiye, Erzurum, Turkey. 3. Department of Dermatology, Katip Çelebi University Ataturk Education and Research Hospital, İzmir, Turkey.
Abstract
PURPOSE: Nutrition and inflammation play a crucial role in the development of cancer. The prognostic value of the prognostic nutritional index (PNI) has been confirmed in some types of human cancers. However, few studies are available indicating its prognostic power in patients with malignant melanoma (MM). Thus, we aimed to identify baseline peripheral blood biomarkers to predict the outcome of MM patients MATERIAL AND METHODS: Data of 101 patients with MM were evaluated retrospectively. Associations between clinical and histopathological parameters with overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and compared by the log-rank test. The optimal cutoff values were determined by a receiver operating characteristic (ROC) curve analysis. Neutrophil-lymphocyte ratio (NLR), systemic immune-inflammation index (SII) and PNI were grouped based on a cutoff points 2.18, 547.1, and 40.1, respectively. Univariate and multivariate analyses were used to assess their prognostic values for overall survival (OS). RESULTS: Lower NLR ( < 2.18), SII ( < 547.1) and higher PNI ( ≥ 40.1) were linked with a longer PFS and OS in patients with MM, as reflected in the Kaplan-Meier analyses. In univariate analysis, TNM stage, Breslow thickness, Clark stage, ulceration, Ki67 status, LDH, NLR, SII, and PNI were significantly associated with OS. Multivariate analysis identified TNM stage, ulceration, LDH and PNI as an independent predictor of OS in patients with MM. CONCLUSION: PNI can be regarded as a novel independent prognostic factor for predicting OS in MM.
PURPOSE: Nutrition and inflammation play a crucial role in the development of cancer. The prognostic value of the prognostic nutritional index (PNI) has been confirmed in some types of humancancers. However, few studies are available indicating its prognostic power in patients with malignant melanoma (MM). Thus, we aimed to identify baseline peripheral blood biomarkers to predict the outcome of MM patients MATERIAL AND METHODS: Data of 101 patients with MM were evaluated retrospectively. Associations between clinical and histopathological parameters with overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan-Meier curves and compared by the log-rank test. The optimal cutoff values were determined by a receiver operating characteristic (ROC) curve analysis. Neutrophil-lymphocyte ratio (NLR), systemic immune-inflammation index (SII) and PNI were grouped based on a cutoff points 2.18, 547.1, and 40.1, respectively. Univariate and multivariate analyses were used to assess their prognostic values for overall survival (OS). RESULTS: Lower NLR ( < 2.18), SII ( < 547.1) and higher PNI ( ≥ 40.1) were linked with a longer PFS and OS in patients with MM, as reflected in the Kaplan-Meier analyses. In univariate analysis, TNM stage, Breslow thickness, Clark stage, ulceration, Ki67 status, LDH, NLR, SII, and PNI were significantly associated with OS. Multivariate analysis identified TNM stage, ulceration, LDH and PNI as an independent predictor of OS in patients with MM. CONCLUSION: PNI can be regarded as a novel independent prognostic factor for predicting OS in MM.
Authors: E Jabłońska; M Kiluk; W Markiewicz; L Piotrowski; Z Grabowska; J Jabłoński Journal: Arch Immunol Ther Exp (Warsz) Date: 2001 Impact factor: 4.291
Authors: Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay Journal: Cancer Res Date: 2009-06-23 Impact factor: 12.701
Authors: Paul Johannet; Amelia Sawyers; Yingzhi Qian; Samuel Kozloff; Nicholas Gulati; Douglas Donnelly; Judy Zhong; Iman Osman Journal: J Immunother Cancer Date: 2020-11 Impact factor: 13.751